Regulatory Coordinator
Full course · Inspection Readiness and Regulatory Quality Management
Free Lesson Preview
View the Regulatory Coordinator track for current pricing and enrollment options.
View enrollment optionsAlready enrolled? Sign in
Teaches how to aggregate quality data across multiple studies to detect systemic site-level issues invisible within any single study, how to distinguish genuine systemic trends from coincidental co-occurrence, and how to design a periodic cross-study review process on a defined schedule.
Lesson 1 built the portfolio compliance dashboard -- the tool that answers "where is the compliance risk in my portfolio right now?" That dashboard is indispensable. But it has a blind spot, and the blind spot is this: the dashboard displays the status of each study independently. Study 004 has an amber delegation finding. Study 011 has an amber delegation finding. Study 017 has an amber delegation finding. The dashboard shows three amber cells in the delegation column. The RC addresses each one.
What the dashboard does not show -- what it cannot show, because it was not designed for this purpose -- is whether those three findings share a common cause. Are three separate studies exhibiting the same type of delegation deficiency because the site's onboarding process has a systemic gap? Or are these three independent findings that happen to fall in the same domain?
That question matters enormously, and not in an abstract way. If the cause is systemic, fixing each study individually is a game of whack-a-mole. The RC resolves the delegation issue in Study 004, and six weeks later it reappears in Study 022 because the underlying onboarding process was never corrected. If the cause is coincidental -- Study 004 had a staff departure, Study 011 had a protocol amendment adding new procedures, Study 017 had an administrative oversight -- then the individual fixes are appropriate and no systemic action is needed.
Cross-study trend analysis is the discipline of answering that question. It is, in my view, the single most valuable analytical capability a regulatory coordinator can develop at the portfolio level, because it surfaces the problems that individual study reviews -- no matter how thorough -- structurally cannot detect.
What you will learn3 objectives
By the end of this lesson, you will be able to:
Progress saves itself — finish reading and this lesson completes
